-
1
-
-
70449704111
-
Clinical pharmacokinetics of tyrosine kinase inhibitors
-
van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 35(8):692-706.
-
(2009)
Cancer Treat Rev
, vol.35
, Issue.8
, pp. 692-706
-
-
Van Erp, N.P.1
Gelderblom, H.2
Guchelaar, H.J.3
-
2
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
DOI 10.1016/S0140-6736(06)69446-4, PII S0140673606694464
-
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J et al: Effcacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet (2006) 368(9544):1329-1338. (Pubitemid 44528723) (Pubitemid 44528723)
-
(2006)
Lancet
, vol.368
, Issue.9544
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
Blackstein, M.E.4
Shah, M.H.5
Verweij, J.6
McArthur, G.7
Judson, I.R.8
Heinrich, M.C.9
Morgan, J.A.10
Desai, J.11
Fletcher, C.D.12
George, S.13
Bello, C.L.14
Huang, X.15
Baum, C.M.16
Casali, P.G.17
-
3
-
-
22044442973
-
Tyrosine kinases as targets for cancer therapy
-
DOI 10.1056/NEJMra044389
-
Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 353(2):172-187. (Pubitemid 41058349) (Pubitemid 41058349)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.2
, pp. 172-187
-
-
Krause, D.S.1
Van Etten, R.A.2
-
4
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
DOI 10.1126/science.1062538
-
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplifcation. Science (2001) 293(5531):876-880. (Pubitemid 32743979) (Pubitemid 32743979)
-
(2001)
Science
, vol.293
, Issue.5531
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Nagesh Rao, P.6
Sawyers, C.L.7
-
5
-
-
0001686739
-
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
-
DOI 10.1016/S1535-6108(02)00096-X
-
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL: Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117-125. (Pubitemid 41039112) (Pubitemid 41039112)
-
(2002)
Cancer Cell
, vol.2
, Issue.2
, pp. 117-125
-
-
Shah, N.P.1
Nicoll, J.M.2
Nagar, B.3
Gorre, M.E.4
Paquette, R.L.5
Kuriyan, J.6
Sawyers, C.L.7
-
6
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
DOI 10.1056/NEJMoa044238
-
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N Engl J Med (2005) 352(8):786-792. (Pubitemid 40271173) (Pubitemid 40271173)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.8
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
Johnson, B.E.7
Eck, M.J.8
Tenen, D.G.9
Halmos, B.10
-
7
-
-
2342624080
-
EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
-
DOI 10.1126/science.1099314
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K et al: EGFR mutations in lung cancer: Correlation with clinical response to geftinib therapy. Science (2004) 304(5676):1497-1500. (Pubitemid 38720929) (Pubitemid 38720929)
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
8
-
-
66849106721
-
Using germline genotype in cancer pharmacogenetic studies
-
McWhinney SR, McLeod HL: Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics (2009) 10(3): 489-493.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.3
, pp. 489-493
-
-
McWhinney, S.R.1
McLeod, H.L.2
-
9
-
-
27644596456
-
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib
-
DOI 10.1038/sj.leu.2403935, PII 2403935
-
Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW: A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia (2005) 19(11):1859-1862. (Pubitemid 41553992) (Pubitemid 41553992)
-
(2005)
Leukemia
, vol.19
, Issue.11
, pp. 1859-1862
-
-
Crossman, L.C.1
O'Hare, T.2
Lange, T.3
Willis, S.G.4
Stoffregen, E.P.5
Corbin, A.S.6
O'Brien, S.G.7
Heinrich, M.C.8
Druker, B.J.9
Middleton, P.G.10
Deininger, M.W.N.11
-
11
-
-
4544290436
-
Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms
-
DOI 10.1016/j.leukres.2004.03.007, PII S014521260400092X
-
Bruck P, Wassmann B, Lopez ER, Hoelzer D, Ottmann OG: Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. Leuk Res (2004) 28(11): 1153-1157. (Pubitemid 39243238) (Pubitemid 39243238)
-
(2004)
Leukemia Research
, vol.28
, Issue.11
, pp. 1153-1157
-
-
Bruck, P.1
Wassmann, B.2
Lopez, E.R.3
Hoelzer, D.4
Ottmann, O.G.5
-
12
-
-
77953968068
-
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
-
Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, Lipton JH: Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol (2010) 21(6):1179-1188.
-
(2010)
Ann Oncol
, vol.21
, Issue.6
, pp. 1179-1188
-
-
Kim, D.H.1
Xu, W.2
Kamel-Reid, S.3
Liu, X.4
Jung, C.W.5
Kim, S.6
Lipton, J.H.7
-
13
-
-
1842426649
-
Correlation of Major Cytogenetic Response with a Pharmacogenetic Marker in Chronic Myeloid Leukemia Patients Treated with Imatinib (STI571)
-
DOI 10.1158/1078-0432.CCR-0785-3
-
Dressman MA, Malinowski R, McLean LA, Gathmann I, Capdeville R, Hensley M, Polymeropoulos MH, International Randomized Study of Interferon-α versus ST1571 Study Group: Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res (2004) 10(7):2265-2271. (Pubitemid 38445683) (Pubitemid 38445683)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.7
, pp. 2265-2271
-
-
Dressman, M.A.1
Malinowski, R.2
McLean, L.A.3
Gathmann, I.4
Capdeville, R.5
Hensley, M.6
Polymeropoulos, M.H.7
-
14
-
-
33746741049
-
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib
-
DOI 10.1016/j.clpt.2006.05.003, PII S0009923606001731
-
Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD et al: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther (2006) 80(2):192-201. (Pubitemid 44160695) (Pubitemid 44160695)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.80
, Issue.2
, pp. 192-201
-
-
Gardner, E.R.1
Burger, H.2
Van Schaik, R.H.3
Van Oosterom, A.T.4
De Bruijn, E.A.5
Guetens, G.6
Prenen, H.7
De Jong, F.A.8
Baker, S.D.9
Bates, S.E.10
Figg, W.D.11
Verweij, J.12
Sparreboom, A.13
Nooter, K.14
-
15
-
-
58149214370
-
Innovative Therapies with Children with Cancer European Consortium: Population pharmacokinetics and pharmaco-genetics of imatinib in children and adults
-
Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, Barrois M, Séronie-Vivien S, LeCesne A, Vassal G, Innovative Therapies with Children with Cancer European Consortium: Population pharmacokinetics and pharmaco-genetics of imatinib in children and adults. Clin Cancer Res (2008) 14(21):7102-7109.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.21
, pp. 7102-7109
-
-
Petain, A.1
Kattygnarath, D.2
Azard, J.3
Chatelut, E.4
Delbaldo, C.5
Geoerger, B.6
Barrois, M.7
Séronie-Vivien, S.8
Lecesne, A.9
Vassal, G.10
-
16
-
-
34250676807
-
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype
-
DOI 10.1038/sj.clpt.6100201, PII 6100201
-
Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE et al: Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther (2007) 82(1):33-40. (Pubitemid 46944197) (Pubitemid 46944197)
-
(2007)
Clinical Pharmacology and Therapeutics
, vol.82
, Issue.1
, pp. 33-40
-
-
Gurney, H.1
Wong, M.2
Balleine, R.L.3
Rivory, L.P.4
McLachlan, A.J.5
Hoskins, J.M.6
Wilcken, N.7
Clarke, C.L.8
Mann, G.J.9
Collins, M.10
Delforce, S.-E.11
Lynch, K.12
Schran, H.13
-
17
-
-
68049087941
-
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia
-
Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH: Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res (2009) 15(14):4750-4758.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.14
, pp. 4750-4758
-
-
Kim, D.H.1
Sriharsha, L.2
Xu, W.3
Kamel-Reid, S.4
Liu, X.5
Siminovitch, K.6
Messner, H.A.7
Lipton, J.H.8
-
18
-
-
52649177063
-
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
-
Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2008) 112(5):2024-2027.
-
(2008)
Blood
, vol.112
, Issue.5
, pp. 2024-2027
-
-
Dulucq, S.1
Bouchet, S.2
Turcq, B.3
Lippert, E.4
Etienne, G.5
Reiffers, J.6
Molimard, M.7
Krajinovic, M.8
Mahon, F.X.9
-
19
-
-
57049129248
-
OCT1 (SLC22A1) R 1C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients
-
Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D: OCT1 (SLC22A1) R 1C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma (2008) 49(11):2222-2223.
-
(2008)
Leuk Lymphoma
, vol.49
, Issue.11
, pp. 2222-2223
-
-
Zach, O.1
Krieger, O.2
Foedermayr, M.3
Zellhofer, B.4
Lutz, D.5
-
20
-
-
40849147041
-
EGFR antagonists in cancer treatment
-
Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med (2008) 358(11):1160-1174.
-
(2008)
N Engl J Med
, vol.358
, Issue.11
, pp. 1160-1174
-
-
Ciardiello, F.1
Tortora, G.2
-
21
-
-
69949162760
-
Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y et al: Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361(10):947-957.
-
(2009)
N Engl J Med
, vol.361
, Issue.10
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
Sunpaweravong, P.7
Han, B.8
Margono, B.9
Ichinose, Y.10
Nishiwaki, Y.11
-
22
-
-
69949186250
-
Screening for epidermal growth factor receptor mutations in lung cancer
-
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 361(10):958-967.
-
(2009)
N Engl J Med
, vol.361
, Issue.10
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
Porta, R.4
Cardenal, F.5
Camps, C.6
Majem, M.7
Lopez-Vivanco, G.8
Isla, D.9
Provencio, M.10
Insa, A.11
-
23
-
-
0040886242
-
Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1
-
Gebhardt F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem (1999) 274(19): 13176-13180.
-
(1999)
J Biol Chem
, vol.274
, Issue.19
, pp. 13176-13180
-
-
Gebhardt, F.1
Zanker, K.S.2
Brandt, B.3
-
24
-
-
61449182121
-
Principles of cancer therapy: Oncogene and non-oncogene addiction
-
Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell (2009) 136(5): 823-837.
-
(2009)
Cell
, vol.136
, Issue.5
, pp. 823-837
-
-
Luo, J.1
Solimini, N.L.2
Elledge, S.J.3
-
25
-
-
10844264628
-
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
-
DOI 10.1158/0008-5472.CAN-04-1036
-
Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 64(24): 9139-9143. (Pubitemid 39665528) (Pubitemid 39665528)
-
(2004)
Cancer Research
, vol.64
, Issue.24
, pp. 9139-9143
-
-
Amador, M.L.1
Oppenheimer, D.2
Perea, S.3
Maitra, A.4
Cusati, G.5
Iacobuzio-Donahue, C.6
Baker, S.D.7
Ashfaq, R.8
Takimoto, C.9
Forastiere, A.10
Hidalgo, M.11
-
26
-
-
34250828460
-
Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response
-
DOI 10.1245/s10434-007-9409-5
-
Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP: Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism infuences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol (2007) 14(7):2150-2158. (Pubitemid 46988271) (Pubitemid 46988271)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.7
, pp. 2150-2158
-
-
Tzeng, C.-W.D.1
Frolov, A.2
Frolova, N.3
Jhala, N.C.4
Howard, J.H.5
Vickers, S.M.6
Buchsbaum, D.J.7
Heslin, M.J.8
Arnoletti, J.P.9
-
27
-
-
67349206986
-
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with geftinib treatment
-
Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY, Lin ZZ, Yu CJ, Cheng AL, Yang PC: EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with geftinib treatment. Lung Cancer (2009) 64(3):346-351.
-
(2009)
Lung Cancer
, vol.64
, Issue.3
, pp. 346-351
-
-
Huang, C.L.1
Yang, C.H.2
Yeh, K.H.3
Hu, F.C.4
Chen, K.Y.5
Shih, J.Y.6
Lin, Z.Z.7
Yu, C.J.8
Cheng, A.L.9
Yang, P.C.10
-
28
-
-
34247281406
-
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
-
DOI 10.1097/FPC.0b013e328011abc0, PII 0121301120070500000002
-
Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS et al: Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and geftinib responsiveness in non-small-cell lung cancer. Pharmacogenet Genomics (2007) 17(5):313-319. (Pubitemid 46608538) (Pubitemid 46608538)
-
(2007)
Pharmacogenetics and Genomics
, vol.17
, Issue.5
, pp. 313-319
-
-
Han, S.-W.1
Jeon, Y.K.2
Lee, K.-H.3
Keam, B.4
Hwang, P.G.5
Oh, D.-Y.6
Lee, S.-H.7
Kim, D.-W.8
Im, S.-A.9
Chung, D.H.10
Heo, D.S.11
Bang, Y.-J.12
Kim, T.-Y.13
-
29
-
-
68949208058
-
Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with geftinib
-
Ma F, Sun T, Shi Y, Yu D, Tan W, Yang M, Wu C, Chu D, Sun Y, Xu B, Lin D: Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with geftinib. Lung Cancer (2009) 66(1):114-119.
-
(2009)
Lung Cancer
, vol.66
, Issue.1
, pp. 114-119
-
-
Ma, F.1
Sun, T.2
Shi, Y.3
Yu, D.4
Tan, W.5
Yang, M.6
Wu, C.7
Chu, D.8
Sun, Y.9
Xu, B.10
Lin, D.11
-
30
-
-
34547841540
-
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib
-
DOI 10.1016/j.ejphar.2007.05.015, PII S0014299907006140
-
Nie Q, Wang Z, Zhang GC, An SJ, Lin JY, Guo AL, Li R, Gan B, Huang Y, Mok TS, Wu YL: The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with geftinib. Eur J Pharmacol (2007) 570(1-3):175-181. (Pubitemid 47247671) (Pubitemid 47247671)
-
(2007)
European Journal of Pharmacology
, vol.570
, Issue.1-3
, pp. 175-181
-
-
Nie, Q.1
Wang, Z.2
Zhang, G.-c.3
An, S.-j.4
Lin, J.-y.5
Guo, A.-l.6
Li, R.7
Gan, B.8
Huang, Y.9
Mok, T.S.10
Wu, Y.-l.11
-
31
-
-
40949096067
-
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
-
DOI 10.1038/sj.tpj.6500444, PII 6500444
-
Liu G, Gurubhagavatula S, Zhou W, Wang Z, Yeap BY, Asomaning K, Su L, Heist R, Lynch TJ, Christiani DC: Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with geftinib. Pharmacogenomics J (2008) 8(2):129-138. (Pubitemid 351411549) (Pubitemid 351411549)
-
(2008)
Pharmacogenomics Journal
, vol.8
, Issue.2
, pp. 129-138
-
-
Liu, G.1
Gurubhagavatula, S.2
Zhou, W.3
Wang, Z.4
Yeap, B.Y.5
Asomaning, K.6
Su, L.7
Heist, R.8
Lynch, T.J.9
Christiani, D.C.10
-
32
-
-
75749153247
-
Predictors of geftinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
-
Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R et al: Predictors of geftinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer (2010) 67(3):355-360.
-
(2010)
Lung Cancer
, vol.67
, Issue.3
, pp. 355-360
-
-
Tiseo, M.1
Rossi, G.2
Capelletti, M.3
Sartori, G.4
Spiritelli, E.5
Marchioni, A.6
Bozzetti, C.7
De Palma, G.8
Lagrasta, C.9
Campanini, N.10
Camisa, R.11
-
33
-
-
41949140593
-
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity
-
Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL et al: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 26(7):1119-1127.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1119-1127
-
-
Rudin, C.M.1
Liu, W.2
Desai, A.3
Karrison, T.4
Jiang, X.5
Janisch, L.6
Das, S.7
Ramirez, J.8
Poonkuzhali, B.9
Schuetz, E.10
Fackenthal, D.L.11
-
34
-
-
33644841038
-
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin effcacy in patients with advanced colorectal cancer
-
Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K et al: Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin effcacy in patients with advanced colorectal cancer. Clin Colorectal Cancer (2005) 5(2):124-131.
-
(2005)
Clin Colorectal Cancer
, vol.5
, Issue.2
, pp. 124-131
-
-
Zhang, W.1
Stoehlmacher, J.2
Park, D.J.3
Yang, D.4
Borchard, E.5
Gil, J.6
Tsao-Wei, D.D.7
Yun, J.8
Gordon, M.9
Press, O.A.10
Rhodes, K.11
-
35
-
-
11244319884
-
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter
-
Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, Ratain MJ: A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 65(1):46-53. (Pubitemid 40070794) (Pubitemid 40070794)
-
(2005)
Cancer Research
, vol.65
, Issue.1
, pp. 46-53
-
-
Liu, W.1
Innocenti, F.2
Wu, M.H.3
Desai, A.A.4
Dolan, M.E.5
Cook Jr., E.H.6
Ratain, M.J.7
-
36
-
-
39449096577
-
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib
-
DOI 10.1038/sj.clpt.6100320, PII 6100320
-
Gregorc V, Hidalgo M, Spreafco A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E et al: Germline polymorphisms in EGFR and survival in patients with lung cancer receiving geftinib. Clin Pharmacol Ther (2008) 83(3):477-484. (Pubitemid 351272637) (Pubitemid 351272637)
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.83
, Issue.3
, pp. 477-484
-
-
Gregorc, V.1
Hidalgo, M.2
Spreafico, A.3
Cusatis, G.4
Ludovini, V.5
Ingersoll, R.G.6
Marsh, S.7
Steinberg, S.M.8
Vigano, M.G.9
Ghio, D.10
Villa, E.11
Sparreboom, A.12
Baker, S.D.13
-
37
-
-
33845657889
-
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
-
DOI 10.1093/jnci/djj469
-
Cusatis G, Gregorc V, Li J, Spreafco A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD: Pharmacogenetics of ABCG2 and adverse reactions to geftinib. J Natl Cancer Inst (2006) 98(23):1739-1742. (Pubitemid 44942712) (Pubitemid 44942712)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.23
, pp. 1739-1742
-
-
Cusatis, G.1
Gregorc, V.2
Li, J.3
Spreafico, A.4
Ingersoll, R.G.5
Verweij, J.6
Ludovini, V.7
Villa, E.8
Hidalgo, M.9
Sparreboom, A.10
Baker, S.D.11
-
38
-
-
36549047976
-
Pharmacogenetics of EGFR and VEGF inhibition
-
DOI 10.1016/j.drudis.2007.10.016, PII S1359644607004564
-
Pander J, Gelderblom H, Guchelaar HJ: Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today (2007) 12(23-24):1054-1060. (Pubitemid 350180563) (Pubitemid 350180563)
-
(2007)
Drug Discovery Today
, vol.12
, Issue.23-24
, pp. 1054-1060
-
-
Pander, J.1
Gelderblom, H.2
Guchelaar, H.-J.3
-
39
-
-
68749095215
-
Population pharmacokinetics of erlotinib and its pharmacokinetic/ pharmacodynamic relationships in head and neck squamous cell carcinoma
-
Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP: Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer (2009) 45(13):2316-2323.
-
(2009)
Eur J Cancer
, vol.45
, Issue.13
, pp. 2316-2323
-
-
Thomas, F.1
Rochaix, P.2
White-Koning, M.3
Hennebelle, I.4
Sarini, J.5
Benlyazid, A.6
Malard, L.7
Lefebvre, J.L.8
Chatelut, E.9
Delord, J.P.10
-
40
-
-
34548240764
-
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
-
Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD: Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 6(3):432-438. (Pubitemid 47328313) (Pubitemid 47328313)
-
(2007)
Cancer Biology and Therapy
, vol.6
, Issue.3
, pp. 432-438
-
-
Li, J.1
Cusatis, G.2
Brahmer, J.3
Sparreboom, A.4
Robey, R.W.5
Bates, S.E.6
Hidalgo, M.7
Baker, S.D.8
-
42
-
-
70349342710
-
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
-
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ et al: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 27(26):4406-4412.
-
(2009)
J Clin Oncol
, vol.27
, Issue.26
, pp. 4406-4412
-
-
Van Erp, N.P.1
Eechoute, K.2
Van Der Veldt, A.A.3
Haanen, J.B.4
Reyners, A.K.5
Mathijssen, R.H.6
Boven, E.7
Van Der Straaten, T.8
Baak-Pablo, R.F.9
Wessels, J.A.10
Guchelaar, H.J.11
-
43
-
-
35648936586
-
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
-
DOI 10.1038/sj.leu.2404827, PII 2404827
-
Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG: UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia (2007) 21(11):2311-2315. (Pubitemid 350019230) (Pubitemid 350019230)
-
(2007)
Leukemia
, vol.21
, Issue.11
, pp. 2311-2315
-
-
Singer, J.B.1
Shou, Y.2
Giles, F.3
Kantarjian, H.M.4
Hsu, Y.5
Robeva, A.S.6
Rae, P.7
Weitzman, A.8
Meyer, J.M.9
Dugan, M.10
Ottmann, O.G.11
-
44
-
-
84971580244
-
Absence of evidence is not evidence of absence
-
Altman DG, Bland JM: Absence of evidence is not evidence of absence. BMJ (1995) 311(7003):485.
-
(1995)
BMJ
, vol.311
, Issue.7003
, pp. 485
-
-
Altman, D.G.1
Bland, J.M.2
-
45
-
-
27844492326
-
Combinatorial pharmacogenetics
-
DOI 10.1038/nrd1874, PII N1874
-
Wilke RA, Reif DM, Moore JH: Combinatorial pharmacogenetics. Nat Rev Drug Discov (2005) 4(11):911-918. (Pubitemid 41637693) (Pubitemid 41637693)
-
(2005)
Nature Reviews Drug Discovery
, vol.4
, Issue.11
, pp. 911-918
-
-
Wilke, R.A.1
Reif, D.M.2
Moore, J.H.3
-
46
-
-
73949120791
-
Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate effcacy and tolerability in rheumatoid arthritis
-
Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM: Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate effcacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics (2009) 19(12):935-944.
-
(2009)
Pharmacogenet Genomics
, vol.19
, Issue.12
, pp. 935-944
-
-
Dervieux, T.1
Wessels, J.A.2
Van Der Straaten, T.3
Penrod, N.4
Moore, J.H.5
Guchelaar, H.J.6
Kremer, J.M.7
|